We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

94 hedge funds and large institutions have $119M invested in AVEO Pharmaceuticals, Inc. in 2018 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 30 increasing their positions, 13 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

552% more call options, than puts

Call options by funds: $13.7M | Put options by funds: $2.1M

131% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 13

24% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 25

4% more funds holding

Funds holding: 90 → 94 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

31% less capital invested

Capital invested by funds: $173M → $119M (-$54.5M)

Holders
94
Holders Change
+4
Holders Change %
+4.44%
% of All Funds
2.15%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
31
Increased
30
Reduced
13
Closed
25
Calls
$13.7M
Puts
$2.1M
Net Calls
+$11.6M
Net Calls Change
+$2.55M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.1M
2
NMC
NEA Management Company
Maryland
+$3.37M
3
State Street
State Street
Massachusetts
+$3.36M
4
Northern Trust
Northern Trust
Illinois
+$2.08M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.12M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$9.37M
2
Millennium Management
Millennium Management
New York
-$3.9M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.73M
4
PM
Prosight Management
Texas
-$2.12M
5
Goldman Sachs
Goldman Sachs
New York
-$1.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$40.1M +$3.37M +142,103 +9%
BlackRock
2
BlackRock
New York
$15.8M +$12.1M +510,128 +272%
RCM
3
RA Capital Management
Massachusetts
$11.4M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$11.3M +$1.12M +47,364 +10%
Millennium Management
5
Millennium Management
New York
$5.68M -$3.9M -164,407 -40%
6CM
6
683 Capital Management
New York
$5.65M – – –
PA
7
Perceptive Advisors
New York
$4.27M -$1.34M -56,693 -23%
State Street
8
State Street
Massachusetts
$3.53M +$3.36M +141,857 +1,004%
Northern Trust
9
Northern Trust
Illinois
$2.48M +$2.08M +87,671 +396%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.21M +$736K +31,058 +46%
DVC
11
Deer VI & Co
New York
$1.53M – – –
EWM
12
Evercore Wealth Management
New York
$946K – – –
NLVP
13
New Leaf Venture Partners
New York
$909K -$1.33M -56,240 -58%
A
14
Abingworth
United Kingdom
$900K +$948K +40,000 New
Two Sigma Advisers
15
Two Sigma Advisers
New York
$895K +$78.5K +3,310 +9%
BCM
16
Bridgeway Capital Management
Texas
$783K – – –
BRWA
17
B. Riley Wealth Advisors
Florida
$713K +$180K +7,580 +32%
Morgan Stanley
18
Morgan Stanley
New York
$703K +$281K +11,854 +62%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$651K +$503K +21,206 +279%
AIM
20
Assured Investment Management
New York
$584K +$29.1K +1,228 +5%
Group One Trading
21
Group One Trading
Illinois
$566K +$406K +17,135 +217%
XSC
22
X-Square Capital
Puerto Rico
$541K +$18.5K +781 +3%
TCIM
23
TIAA CREF Investment Management
New York
$510K +$535K +22,578 New
Charles Schwab
24
Charles Schwab
California
$493K +$449K +18,950 +662%
Deutsche Bank
25
Deutsche Bank
Germany
$439K +$460K +19,402 New
1
2 3 4 5

AVEO Hedge Fund Activity: Q2 2018 in Review

94 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2018, worth a combined $119M — down 31% from $173M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new AVEO positions and 25 closed out — a net gain of 6 holders — while 30 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $12.1M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $9.37M sold.

  • 94 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2018, up from 90 in Q1 2018.
  • Funds reported $119M of AVEO Pharmaceuticals, Inc. stock for Q2 2018, down 31% quarter-over-quarter.
  • 31 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2018 and 25 closed out, a net change of +6 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2018 was BlackRock, an estimated $12.1M added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q2 2018 was Avoro Capital Advisors, an estimated $9.37M sold.

Based on aggregated 13F filings for Q2 2018.